Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

British Journal of Haematology

Volumn 155, Issue 2, 2011, Pages 244-247

  Frandsen, Thomas L ^a   Abrahamsson, Jonas ^b   Lausen, Birgitte ^a   Vettenranta, Kim ^c   Heyman, Mats ^d   Behrentz, Michael ^e   Castor, Anders ^f   Wehner, Peder S ^g   Frost, Britt marie ^h   Andersen, Elisabeth W ⁱ   Schmiegelow, Kjeld ^a,j  

^a Rigshospitalet   (Denmark)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

^h UPPSALA UNIVERSITY HOSPITAL   (Sweden)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

Acute lymphoblastic leukaemia; Chemotherapy; Children; Consolidation; Purine analogues

Indexed keywords

DRUG METABOLITE; MERCAPTOPURINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; FEASIBILITY STUDY; HUMAN; LEUKEMIA REMISSION; LIVER TOXICITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; PAIN; PANCREATITIS; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FEVER; HUMANS; INDIVIDUALIZED MEDICINE; INFANT; MALE; METHOTREXATE; MUCOSITIS; PANCREATITIS; PILOT PROJECTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 80053567424     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08835.x     Document Type: Article

References (15)

1. Avramis, V.I. & Spence, S.A. (2007) Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. Journal of Pediatric Hematology and Oncology, 29, 239-247.
2. Bruunshuus, I. & Schmiegelow, K. (1989) Analysis of 6-mercaptopurine, 6-thioguanine nucleotides, and 6-thiouric acid in biological fluids by high-performance liquid chromatography. Scandinavian Journal of Clinical and Laboratory Investigation, 49, 779-784.
3. Davidsen, M.L., Dalhoff, K. & Schmiegelow, K. (2008) Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. Journal of Pediatric Hematoogy and Oncology, 30, 831-849.
4. Evans, W.E., Relling, M.V., Rodman, J.H., Crom, W.R., Boyett, J.M. & Pui, C.H. (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. New England Journal of Medicine, 338, 499-505.
5. Kamen, B.A., Takach, P.L., Vatev, R. & Caston, J.D. (1976) A rapid, radiochemical-ligand binding assay for methotrexate. Annals of Biochemistry, 70, 54-63.
6. van Kooten Niekerk, P.B., Schmiegelow, K. & Schroeder, H. (2008) Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate. European Journal of Haematology, 81, 391-398.
7. Moe, P.J. & Holen, A. (2000) High-dose methotrexate in childhood all. Pediatric Hematology and Oncology, 17, 615-622.
8. Nygaard, U. & Schmiegelow, K. (2003) Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia. Leukemia, 17, 1344-1348.
9. Otterness, D., Szumlanski, C., Lennard, L., Klemetsdal, B., Aarbakke, J., Park-Hah, J.O., Iven, H., Schmiegelow, K., Branum, E., O'Brien, J. & Weinshilboum, R. (1997) Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clinical Pharmacology and Therapeutics, 62, 60-73.
10. Schmiegelow, K. & Ifversen, M. (1996) Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia. Pediatric Hematology and Oncology, 13, 433-441.
11. Schmiegelow, K., Bjork, O., Glomstein, A., Gustafsson, G., Keiding, N., Kristinsson, J., Makipernaa, A., Rosthoj, S., Szumlanski, C., Sorensen, T.M. & Weinshilboum, R. (2003) Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. Journal of Clinical Oncology, 21, 1332-1339.
12. Schmiegelow, K., Forestier, E., Kristinsson, J., Soderhall, S., Vettenranta, K., Weinshilboum, R. & Wesenberg, F. (2009a) Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia, 23, 557-564.
13. Schmiegelow, K., Al-Modhwahi, I., Andersen, M.K., Behrendtz, M., Forestier, E., Hasle, H., Heyman, M., Kristinsson, J., Nersting, J., Nygaard, R., Svendsen, A.L., Vettenranta, K. & Weinshilboum, R. (2009b) Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood, 113, 6077-6084.
14. Schmiegelow, K., Forestier, E., Hellebostad, M., Heyman, M., Kristinsson, J., Soderhall, S. & Taskinen, M. (2010) Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia, 24, 345-354.
15. Stanulla, M., Schaeffeler, E., Flohr, T., Cario, G., Schrauder, A., Zimmermann, M., Welte, K., Ludwig, W.D., Bartram, C.R., Zanger, U.M., Eichelbaum, M., Schrappe, M. & Schwab, M. (2005) Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. Journal of the Amarican Medicial Association, 293, 1485-1489.